GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (LTS:0Y3M) » Definitions » Inventories, Other

Prothena (LTS:0Y3M) Inventories, Other : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Prothena Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Prothena's other inventories for the quarter that ended in Dec. 2024 was $0.0 Mil.


Prothena Inventories, Other Historical Data

The historical data trend for Prothena's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Inventories, Other Chart

Prothena Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prothena Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Prothena Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Prothena Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Prothena Headlines

No Headlines